Replies to post #132 on Aida Pharmaceuticals (AIDA)

[wave00]

From 8/19 10-Q:

The Phase I clinical trial of rh-Apo2l has been successfully completed and the Phase II clinical trial has been initiated.


net loss at $0.25 is a dangerous number for a penny stock. With net loss at $0.25, this stock's risk is too high even with current price $0.5. The mutual guarantee business is too risky now--at least 30% of small and medium size company were going bankrupt in Zhejiang recently.